SEARCH RESULT

Total Matching Records found : 400

Why Novartis case will help innovation-Achal Prabhala and Sudhir Krishnaswamy

-The Hindu The Supreme Court judgment on Glivec is a blow for a patent regime with a higher threshold of inventiveness On April 1, 2013, the Supreme Court upheld the Intellectual Property Appellate Board's decision to deny patent protection to Novartis's application covering a beta crystalline form of imatinib -the medicine Novartis brands as Glivec, and which is very effective against the form of cancer known as chronic myeloid leukaemia (CML). The...

More »

HIV, cancer patients seek access to affordable medicines-Aarti Dhar

-The Hindu     Protesters see attempt by EU to undermine Indian judiciary in the EU-FTA pact People living with HIV, cancer patient groups and public health activists came out on the streets on Wednesday demanding that India reject the European Union's demands in the European Union-India Free Trade Agreement (EU-India FTA) negotiations. The protests coincide with Prime Minister Manmohan Singh's visit to Germany to meet Chancellor Angela Merkel with the FTA on top of...

More »

Finally, the patients prevail -Sarah Hiddleston

-The Hindu The Supreme Court has denied Novartis a patent for its anti-cancer drug Gleevec. This leaves the door open for Indian pharmaceutical companies to produce their own versions of the drug. Since these are sold at roughly one tenth of the patented brand price, for thousands of cancer patients it means the difference between medicine and no medicine at all. It is not just cancer patients that will benefit, but...

More »

Glivec lesson for pharma: Patented drugs must be priced smartly-Kiran Mazumdar Shaw

-The Economic Times To ensure access to healthcare for all, India must harness innovation in discovering drugs, in developing therapeutics and in delivering affordable healthcare. It is in the light of these facts that one should evaluate the impact of the Indian Supreme Court's ruling in the case involving patent protection for Novartis AG's cancer drug, Glivec. Glivec was the first-of-its-kind cancer drug for leukaemia patients with patent protection in nearly 40...

More »

An Empty Table at Doha Climate Talks -Stephen Leahy

-IPS News Doha: United Nations climate talks are on the edge of collapse Thursday, according to a coalition of civil society and representatives from half of the world’s countries. Once again, rich industrialised nations are putting nothing on the table in terms of increased emissions cuts and financial support for poor nations, said Celine Charveriat, director of advocacy and campaigns for Oxfam International. “This is just like WTO (World Trade Organisation) negotiations where...

More »

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close